{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:58:33Z","timestamp":1763017113187,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1164,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.bbmt.2011.05.003","type":"journal-article","created":{"date-parts":[[2011,5,12]],"date-time":"2011-05-12T14:30:25Z","timestamp":1305210625000},"page":"302-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Allogeneic Hematopoietic Cell Transplantation for Chronic Myelofibrosis in Australia and New Zealand: Older Recipients Receiving Myeloablative Conditioning at Increased Mortality Risk"],"prefix":"10.1016","volume":"18","author":[{"given":"Ian","family":"Nivison-Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Dodds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth F.","family":"Bradstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.F.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy M.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Szer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2011.05.003_bib1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2011.05.003_bib2","first-page":"2831","volume":"93","author":"Guardiola","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.003_bib3","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.003_bib4","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2141.2001.02796.x","article-title":"Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia","volume":"113","author":"Tefferi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.05.003_bib5","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2007.06497.x","article-title":"The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders","volume":"136","author":"Larsen","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.05.003_bib6","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2006-08-039909","article-title":"Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis","volume":"109","author":"Kroger","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.003_bib7","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.003_bib8","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood.V72.3.855.bloodjournal723855","article-title":"Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases","volume":"72","author":"Demory","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.003_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF01834368","article-title":"Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival","volume":"68","author":"Rupoli","year":"1994","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2011.05.003_bib10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2141.1997.782714.x","article-title":"Identification of \u201cshort-lived\u201d and \u201clong-lived\u201d patients at presentation of idiopathic myelofibrosis","volume":"97","author":"Cervantes","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.05.003_bib11","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.bmt.1705516","article-title":"Allogeneic stem cell transplantation as treatment for myelofibrosis","volume":"38","author":"Papageorgiou","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.003_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbmt.2006.11.004","article-title":"Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia","volume":"13","author":"Kerbauy","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.003_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.bmt.1704075","article-title":"Stem cell transplantation for myelofibrosis: a report from two Canadian centers","volume":"32","author":"Daly","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.003_bib14","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.bmt.1704657","article-title":"Outcome of allogeneic stem cell transplantation in patients with myelofibrosis","volume":"34","author":"Ditschkowski","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.003_bib15","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3324\/haematol.12828","article-title":"Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"93","author":"Patriarca","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2011.05.003_bib16","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2141.2005.05373.x","article-title":"Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis","volume":"128","author":"Kroger","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.05.003_bib17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2141.2006.06302.x","article-title":"Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens","volume":"135","author":"Merup","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.05.003_bib18","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2004-11-4299","article-title":"Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia","volume":"105","author":"Rondelli","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.003_bib19","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.bbmt.2006.06.014","article-title":"Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis","volume":"12","author":"Snyder","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.003_bib20","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for\u00a0Blood and Marrow Transplantation","volume":"114","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.003_bib21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.003_bib22","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/bmt.2010.14","article-title":"The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study","volume":"45","author":"Stewart","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.003_bib23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.bbmt.2007.04.003","article-title":"Hematopoietic stem cell transplantation in Australia and New Zealand, 1992-2004","volume":"13","author":"Nivison-Smith","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.003_bib24","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1056\/NEJM197504172921605","article-title":"Bone-marrow transplantation","volume":"292","author":"Thomas","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2011.05.003_bib25","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1182\/blood-2005-04-1520","article-title":"Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)","volume":"106","author":"Barosi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.003_bib26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/bmt.2008.219","article-title":"A reduced intensity conditioning protocol associated with excellent survival in patients with myelofibrosis","volume":"42","author":"George","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.003_bib27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2141.2010.08417.x","article-title":"Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"152","author":"Robin","year":"2010","journal-title":"Br J Haematol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111002096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111002096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:42:42Z","timestamp":1761057762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879111002096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S1083879111002096"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.05.003","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Hematopoietic Cell Transplantation for Chronic Myelofibrosis in Australia and New Zealand: Older Recipients Receiving Myeloablative Conditioning at Increased Mortality Risk","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}